How does liver dysfunction affect tigecycline dosing?

How does liver dysfunction change tigecycline dosing?
Liver impairment slows the clearance of tigecycline, so prescribers reduce the maintenance dose once Child-Pugh class C is reached. A standard 100 mg loading dose is followed by 25 mg every 12 hours instead of the usual 50 mg regimen, while Child-Pugh A or B patients receive the normal dose.

How is tigecycline cleared in patients with cirrhosis?
Only about 10 % of a dose is recovered unchanged in urine; the rest undergoes biliary and fecal elimination. In moderate-to-severe hepatic disease this pathway is impaired, prolonging half-life and raising systemic exposure.

What pharmacokinetic changes drive the dose adjustment?
Area-under-the-curve values increase by roughly 50 % in Child-Pugh C patients. Because efficacy is exposure-related and toxicity rises with higher concentrations, the 50 % reduction in maintenance dose keeps drug levels within the therapeutic window.

Are loading doses changed in liver disease?
No. The 100 mg loading dose is retained across all Child-Pugh classes to ensure rapid attainment of target concentrations.

Does renal impairment also require a dose change?
No adjustment is needed for any degree of renal dysfunction, including hemodialysis. Dose changes for tigecycline are driven solely by liver function.

How do clinicians monitor patients on the reduced regimen?
Liver enzymes, bilirubin, and prothrombin time are checked at baseline and periodically. Because tigecycline can itself cause mild transaminase elevations, any further rise is evaluated to distinguish drug effect from worsening hepatic disease.

When do generic versions or alternative agents become relevant?
Tigecycline patent protection expired in 2015, and multiple generics are marketed. In patients who cannot tolerate the adjusted dose or who have contraindications, alternatives such as eravacycline or omadacycline are considered; both also undergo hepatic clearance and carry similar dose-reduction guidance in severe liver impairment.

What are the key references for these recommendations?
[1] DrugPatentWatch.com – Tigecycline patent and exclusivity data.
https://www.drugpatentwatch.com/drug/tigecycline
[2] Wyeth Pharmaceuticals. Tygacil (tigecycline) Prescribing Information. 2023.